Last Week’s Hot Topic on Pulmonary Fibrosis

Last Week’s Hot Topic on Pulmonary Fibrosis

Last week’s hot topic on pulmonary fibrosis was Mechanotherapy Promotes Regeneration of Fibrotic Tissues, Study Shows written by Patricia Inacio. This article is focused on researchers who discovered that mechanotherapy on damaged muscle tissue reduces both fibrotic tissue accumulation and inflammation while helping to increase tissue…

Fibrotic Pathways in IPF May Have a Common Protein and New Treatment Target

A motor protein called myosin II was identified in a recent study to be a driver of fibrosis development — a finding with a notable potential to lead to improved treatments for idiopathic pulmonary fibrosis (IPF). The study by  Cleveland Clinic researchers is titled “Matrix-Driven Myosin II Mediates the Pro-Fibrotic Fibroblast Phenotype,“ and was published in the …

Living with IPF: John’s Story

In 2012, John was diagnosed with idiopathic pulmonary fibrosis (IPF), a condition for which there is no known cure. In this video, John explains how the British Lung Foundation is helping him. Learn more about IPF: https://bit.ly/1QiRmr3…

Idiopathic Pulmonary Fibrosis Testimonies

https://www.youtube.com/watch?v=IXDhKZImx8U Watch this video from Healthy Body, Healthy Mind, to learn more about idiopathic pulmonary fibrosis. Three experts and four patients talk about the disease and their experience with it. Learn more about IPF: https://bit.ly/1QiRmr3…

OFEV Now Available to IPF Patients in England and Wales

Boehringer Ingelheim recently announced that OFEV (nintedanib) has been recommended by the National Institute for Health and Care Excellence (NICE) as a treatment for idiopathic pulmonary fibrosis (IPF) within the National Health Service (NHS) in England and in Wales. Nintedanib, an oral small molecule tyrosine kinase inhibitor, is recommended for…